Nephron Architecture
Kidney research
at the cellular level
Electron microscopy, perfusion modeling, and collaborative trials — from a single glomerulus to multi-center RCTs.
Patients Enrolled
Active research cohorts
Global Sites
Collaborative trial network
Avg. Turnaround
Histopathology reads
Active Trials
Phase I–III in enrollment
Annual Referrals
Complex case consultations
Research Conversations
What happens when the
science is taken seriously
"The biomarker collaboration with Nephron changed how I interpret tubular injury markers in early CKD. Their histopathology turnaround let us adjust dosing protocols mid-trial — something I've never been able to do with any other center."
Dr. Camila Ferreira Alves
Transplant Immunologist
Universidade de São Paulo · São Paulo, Brazil
Research Outcome
Patients Enrolled
Across 11 clinical sites in 7 countries
Biomarker validation cohort, CKD stages 2–4
"We'd worked with three academic centers before Nephron. None of them could turn around a histopathology read in under a week. Nephron averaged 72 hours. That alone changed our Phase II timeline by four months."
Dr. Marcus Osei-Bonsu
VP Medical Affairs
Kiral Therapeutics · Basel, Switzerland
Research Outcome
Avg. Histopathology Turnaround
Median 68 hrs across 847 tissue reads in 2025
Electron microscopy + light microscopy panel
"Our glomerular disease cohort was too small for a meaningful RCT on our own. Nephron brought four additional sites within six weeks. The statistical power we gained was the difference between a null result and a publication in JASN."
Dr. Priya Krishnaswamy
Associate Professor of Nephrology
All India Institute of Medical Sciences · New Delhi, India
Research Outcome
Active Trials
Phase I–III studies currently in enrollment
CKD, FSGS, IgAN, dialysis sparing, transplant
"I referred a patient with biopsy-confirmed collapsing FSGS who had failed three immunosuppressive regimens. Nephron's case consultation identified a APOL1 variant that had been missed. She's been in remission for 14 months."
Dr. Yusuf Adeyemi
Director, Nephrology
Lagos University Teaching Hospital · Lagos, Nigeria
Research Outcome
Complex Case Referrals
Patients referred by hospital systems annually
Cases that had exhausted local protocols
Capabilities
Four research areas,
one integrated center
From single-investigator pilots to multi-center RCTs — the infrastructure scales with the question.
CKD Progression
Longitudinal cohort studies and biomarker validation for chronic kidney disease stages 1–5. Specializing in early tubular injury markers, GFR trajectory modeling, and fibrosis quantification via digital pathology.
Dialysis Innovation
Phase I–III trial infrastructure for dialysis-sparing therapies and novel membrane technologies. Perfusion modeling lab with 6 ex-vivo organ platforms, enabling translational pharmacokinetics in human renal tissue.
Transplant Immunology
Antibody-mediated rejection phenotyping, donor-specific antibody monitoring, and protocol biopsy programs. Collaborative networks with 8 transplant centers for multi-site immune profiling studies.
Glomerular Disease
FSGS, IgAN, membranous nephropathy, and rare podocytopathies. Electron microscopy suite with sub-nanometer resolution for podocyte foot process analysis. Genetic panel including APOL1, WT1, NPHS1/2.
Research Partnerships
Start a Research
Conversation
This form is the opening line of a collegial email — not a sales funnel. Tell us what you're investigating. We'll respond within one business day with relevant experience or an honest assessment of fit.
Academic Investigators
Collaborative trials, co-authorship, shared cohorts
Pharmaceutical Partners
Phase I–III CRO services, histopathology, biomarkers
Hospital Referrals
Complex cases that have exhausted local protocols
Not ready to reach out yet?